Literature DB >> 29945995

Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant.

Chao Liu1,2, Theresa Guo3, Guorong Xu4, Akihiro Sakai1, Shuling Ren1,2, Takahito Fukusumi1, Mizuo Ando1, Sayed Sadat1, Yuki Saito1, Zubair Khan3, Kathleen M Fisch4, Joseph Califano5,6.   

Abstract

Purpose: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide, and alternative splicing is considered to play important roles in tumor progression. Our study is designed to identify alternative splicing events (ASEs) in human papillomavirus (HPV)-negative HNSCC.Experimental Design: RNA sequencing data of 407 HPV-negative HNSCC and 38 normal samples were obtained from The Cancer Genome Atlas (TCGA), and splice junctions were discovered using MapSplice. Outlier analysis was used to identify significant splicing junctions between HPV-negative HNSCC and normal samples. To explore the functional role of the identified DOCK5 variant, we checked its expression with qRT-PCR in a separate primary tumor validation set and performed proliferation, migration, and invasion assays.
Results: A total of 580 significant splicing events were identified in HPV-negative HNSCC, and the most common type of splicing events was an alternative start site (33.3%). The prevalence of a given individual ASE among the tumor cohort ranged from 9.8% and 64.4%. Within the 407 HPV-negative HNSCC samples in TCGA, the number of significant ASEs differentially expressed in each tumor ranged from 17 to 290. We identified a novel candidate oncogenic DOCK5 variant confirmed using qRT-PCR in a separate primary tumor validation set. Loss- and gain-of-function experiments indicated that DOCK5 variant promoted proliferation, migration, and invasion of HPV-negative HNSCC cells, and patients with higher expression of DOCK5 variant showed decreased overall survival.Conclusions: Analysis of ASEs in HPV-negative HNSCC identifies multiple alterations likely related to carcinogenesis, including an oncogenic DOCK5 variant. Clin Cancer Res; 24(20); 5123-32. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29945995      PMCID: PMC6440699          DOI: 10.1158/1078-0432.CCR-18-0752

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  56 in total

Review 1.  Alternative splicing: an emerging topic in molecular and clinical oncology.

Authors:  María J Pajares; Teresa Ezponda; Raúl Catena; Alfonso Calvo; Ruben Pio; Luis M Montuenga
Journal:  Lancet Oncol       Date:  2007-04       Impact factor: 41.316

Review 2.  Dock-family exchange factors in cell migration and disease.

Authors:  Gilles Gadea; Anne Blangy
Journal:  Eur J Cell Biol       Date:  2014-06-24       Impact factor: 4.492

3.  The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts.

Authors:  Virginie Vives; Mélanie Laurin; Gaelle Cres; Pauline Larrousse; Zakia Morichaud; Danièle Noel; Jean-François Côté; Anne Blangy
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

4.  A Novel Functional Splice Variant of AKT3 Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers.

Authors:  Theresa Guo; Akihiro Sakai; Bahman Afsari; Michael Considine; Ludmila Danilova; Alexander V Favorov; Srinivasan Yegnasubramanian; Dylan Z Kelley; Emily Flam; Patrick K Ha; Zubair Khan; Sarah J Wheelan; J Silvio Gutkind; Elana J Fertig; Daria A Gaykalova; Joseph Califano
Journal:  Cancer Res       Date:  2017-07-21       Impact factor: 12.701

5.  Pharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation.

Authors:  Virginie Vives; Gaëlle Cres; Christian Richard; Muriel Busson; Yann Ferrandez; Anne-Gaelle Planson; Mahel Zeghouf; Jacqueline Cherfils; Luc Malaval; Anne Blangy
Journal:  Nat Commun       Date:  2015-02-03       Impact factor: 14.919

6.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

7.  Multiple alternative splicing markers for ovarian cancer.

Authors:  Roscoe Klinck; Anne Bramard; Lyna Inkel; Geneviève Dufresne-Martin; Julien Gervais-Bird; Richard Madden; Eric R Paquet; ChuShin Koh; Julian P Venables; Panagiotis Prinos; Manuela Jilaveanu-Pelmus; Raymund Wellinger; Claudine Rancourt; Benoit Chabot; Sherif Abou Elela
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

8.  Splice Expression Variation Analysis (SEVA) for inter-tumor heterogeneity of gene isoform usage in cancer.

Authors:  Bahman Afsari; Theresa Guo; Michael Considine; Liliana Florea; Luciane T Kagohara; Genevieve L Stein-O'Brien; Dylan Kelley; Emily Flam; Kristina D Zambo; Patrick K Ha; Donald Geman; Michael F Ochs; Joseph A Califano; Daria A Gaykalova; Alexander V Favorov; Elana J Fertig
Journal:  Bioinformatics       Date:  2018-06-01       Impact factor: 6.937

Review 9.  Learning dysregulated pathways in cancers from differential variability analysis.

Authors:  Bahman Afsari; Donald Geman; Elana J Fertig
Journal:  Cancer Inform       Date:  2014-10-23

10.  Comprehensive genomic characterization of head and neck squamous cell carcinomas.

Authors: 
Journal:  Nature       Date:  2015-01-29       Impact factor: 49.962

View more
  12 in total

1.  Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.

Authors:  Chao Liu; Sayed H Sadat; Koji Ebisumoto; Akihiro Sakai; Bharat A Panuganti; Shuling Ren; Yusuke Goto; Sunny Haft; Takahito Fukusumi; Mizuo Ando; Yuki Saito; Theresa Guo; Pablo Tamayo; Huwate Yeerna; William Kim; Jacqueline Hubbard; Andrew B Sharabi; J Silvio Gutkind; Joseph A Califano
Journal:  Clin Cancer Res       Date:  2020-01-13       Impact factor: 12.531

2.  Inhibition of cell survival and invasion by Tanshinone IIA via FTH1: A key therapeutic target and biomarker in head and neck squamous cell carcinoma.

Authors:  Wei Mao; Jian Ding; Yu Li; Ruofei Huang; Baoxin Wang
Journal:  Exp Ther Med       Date:  2022-06-16       Impact factor: 2.751

3.  UBE2O Promotes Progression and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.

Authors:  Xiyu Chen; Shuiting Zhang; Chao Liu; Guo Li; Shanhong Lu; Yunyun Wang; Xin Zhang; Donghai Huang; Yuanzheng Qiu; Yong Liu
Journal:  Onco Targets Ther       Date:  2020-06-29       Impact factor: 4.147

4.  Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.

Authors:  Zhi-Xuan Li; Zi-Qi Zheng; Zhuo-Hui Wei; Lu-Lu Zhang; Feng Li; Li Lin; Rui-Qi Liu; Xiao-Dan Huang; Jia-Wei Lv; Fo-Ping Chen; Xiao-Jun He; Jia-Li Guan; Jia Kou; Jun Ma; Guan-Qun Zhou; Ying Sun
Journal:  Theranostics       Date:  2019-10-14       Impact factor: 11.556

Review 5.  Targeting Rac and Cdc42 GEFs in Metastatic Cancer.

Authors:  Maria Del Mar Maldonado; Julia Isabel Medina; Luis Velazquez; Suranganie Dharmawardhane
Journal:  Front Cell Dev Biol       Date:  2020-04-08

6.  Aberrant expression of CPSF1 promotes head and neck squamous cell carcinoma via regulating alternative splicing.

Authors:  Akihiro Sakai; Mizuo Ando; Takahito Fukusumi; Shuling Ren; Chao Liu; Jesse Qualliotine; Sunny Haft; Sayed Sadat; Yuki Saito; Theresa W Guo; Guorong Xu; Roman Sasik; Kathleen M Fisch; J Silvio Gutkind; Elana J Fertig; Alfredo A Molinolo; Joseph A Califano
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.752

7.  Identification and validation of an alternative splicing-based prognostic signature for head and neck squamous cell carcinoma.

Authors:  Xinyuan Zhao; Shanshan Si; Xiaona Li; Wenjuan Sun; Li Cui
Journal:  J Cancer       Date:  2020-05-18       Impact factor: 4.207

8.  Prognostic role of alternative splicing events in head and neck squamous cell carcinoma.

Authors:  Yanni Ding; Guang Feng; Min Yang
Journal:  Cancer Cell Int       Date:  2020-05-14       Impact factor: 5.722

Review 9.  Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.

Authors:  Barbara Seliger; Chiara Massa; Bo Yang; Daniel Bethmann; Matthias Kappler; Alexander Walter Eckert; Claudia Wickenhauser
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

10.  Identification of Novel Alternative Splicing Events Associated With Tumorigenesis, Protein Modification, and Immune Microenvironment in Early-Onset Gastric Cancer.

Authors:  Jian Zhang; Ajay Goel; Lin Zhu
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.